Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TT28S46)

• DTT Name: Leukocyte surface antigen CD47 (CD47) DTT Info
• Gene Name: CD47

Molecule-Related Drug & Molecule List

16 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hu5F9-G4	DMBER0Q	Myelodysplastic syndrome	2A37	Phase 3	[1]
Evorpacept	DMJTX7Q	Gastric cancer	2B72	Phase 2/3	[2]
PF-07901801	DMEVYHR	Diffuse large B-cell lymphoma	2A81	Phase 2	[3]
ALX148	DMGQX0U	Myelodysplastic syndrome	2A37	Phase 1/2	[1]
AO-176	DMXU98C	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[4]
DSP-107	DM8K0PR	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[5]
CC-90002	DMK0QDO	Acute myeloid leukaemia	2A60	Phase 1	[6]
IBI188	DMXUJ1P	Myelodysplastic syndrome	2A37	Phase 1	[7]
IMC-002	DMWSI04	Lymphoma	2A80-2A86	Phase 1	[8]
PF-07257876	DM0E2SW	Non-small-cell lung cancer	2C25	Phase 1	[9]
SL-172154	DMN3D72	Ovarian cancer	2C73	Phase 1	[10]
TG-1801	DM3K4FY	B-cell lymphoma	2A86	Phase 1	[11]
TJC4	DMLUOVS	Lymphoma	2A80-2A86	Phase 1	[12]
TTI-621	DMDNPAV	Haematological malignancy	2B33.Y	Phase 1	[13]
TTI-622	DMOCQ4K	Lymphoma	2A80-2A86	Phase 1	[14]
ZL-1201	DMTNUA4	Solid tumour/cancer	2A00-2F9Z	Phase 1	[15]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2021 Dec;22(12):1740-1751.
• [3] ClinicalTrials.gov (NCT05626322) A PHASE 1b/2 STUDY OF PF-07901801, A CD47 BLOCKING AGENT, WITH TAFASITAMAB AND LENALIDOMIDE FOR PARTICIPANTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION. U.S.National Institutes of Health.
• [4] Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding. Mol Cancer Ther. 2020 Mar;19(3):835-846.
• [5] Clinical pipeline report, company report or official report of KAHR Medical.
• [6] National Cancer Institute Drug Dictionary (drug name CC 90002).
• [7] Clinical pipeline report, company report or official report of Innovent Biologics.
• [8] Clinical pipeline report, company report or official report of ImmuneOncia Therapeutics.
• [9] ClinicalTrials.gov (NCT04881045) A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07257876 IN PATIENTS WITH ADVANCED OR METASTATIC TUMORS. U.S.National Institutes of Health.
• [10] Clinical pipeline report, company report or official report of Shattuck Labs.
• [11] Clinical pipeline report, company report or official report of TG Theraputics.
• [12] Clinical pipeline report, company report or official report of I-MAB Biopharma.
• [13] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [14] Clinical pipeline report, company report or official report of Trillium Therapeutics.
• [15] Clinical pipeline report, company report or official report of ZAI Lab.